<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12919">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442338</url>
  </required_header>
  <id_info>
    <org_study_id>0476-334</org_study_id>
    <secondary_id>MK0476-334</secondary_id>
    <secondary_id>2007_007</secondary_id>
    <nct_id>NCT00442338</nct_id>
  </id_info>
  <brief_title>Study of MK0476 in Adult Patients With Acute Asthma (0476-334)</brief_title>
  <official_title>MK0476 Phase III Open Label Exploratory Comparative Clinical Study -Acute Exacerbations of Asthma -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study estimates the efficacy and safety of MK0476 and aminophylline intravenous
      administration in adult patients with acute asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration</measure>
    <time_frame>60 minutes after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Average of Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at 60 minutes after drug administration</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Montelukast 7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast 14 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aminophylline 250 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>Montelukast single injection of either 7 mg or 14 mg Intravenous Administration</description>
    <arm_group_label>Montelukast 7 mg</arm_group_label>
    <arm_group_label>Montelukast 14 mg</arm_group_label>
    <other_name>MK0476</other_name>
    <other_name>SINGULAIR ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Aminophylline</intervention_name>
    <description>Single injection Aminophylline 250 mg Intravenous Drip Infusion</description>
    <arm_group_label>Aminophylline 250 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with acute asthma attacks

        Exclusion Criteria:

          -  Patient has any known or suspected, acute or chronic cause for their pulmonary
             symptoms other than asthma (e.g., copd, chronic heart failure, etc.).

          -  Patient has a smoking habit (15 cigarettes per day) within a month prior to screening
             period, and/or has a smoking history (20 cigarettes per day) of more than 15 years.

          -  Patient has a disease of the cardiovascular, hepatic, renal, hematologic systems, or
             other severe disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 11, 2015</lastchanged_date>
  <firstreceived_date>February 27, 2007</firstreceived_date>
  <firstreceived_results_date>May 22, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aminophylline</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III.
Studied period: March 12, 2007 (date study drug was first administered to first patient) to August 1, 2007 (date study drug was last administered to last patient). Study was conducted at 31 clinical sites.</recruitment_details>
      <pre_assignment_details>Patients with acute exacerbation of bronchial asthma received standard treatments of inhaled β-agonist or oxygen inhalation to treat the acute exacerbations during the 60 minutes in the screening period before the study randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Montelukast 7 mg</title>
          <description>Montelukast 7 mg Intravenous Administration</description>
        </group>
        <group group_id="P2">
          <title>Montelukast 14 mg</title>
          <description>Montelukast 14 mg Intravenous Administration</description>
        </group>
        <group group_id="P3">
          <title>Aminophylline 250 mg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Montelukast 7 mg</title>
          <description>Montelukast 7 mg Intravenous Administration</description>
        </group>
        <group group_id="B2">
          <title>Montelukast 14 mg</title>
          <description>Montelukast 14 mg Intravenous Administration</description>
        </group>
        <group group_id="B3">
          <title>Aminophylline 250 mg</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="31"/>
                <measurement group_id="B4" value="91"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.0" spread="12.3"/>
                <measurement group_id="B2" value="56.7" spread="15.2"/>
                <measurement group_id="B3" value="55.4" spread="14.5"/>
                <measurement group_id="B4" value="56.0" spread="13.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="62"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Asthma Attack Severity based on Asthma Prevention and Management Guideline 2003, Japan</title>
          <description>Mild (Peak Expiratory Flow: 70%-80%), Moderate (Peak Expiratory Flow: 50%-70%), Severe (Peak Expiratory Flow: &lt;=50%) or Serious (Peak Expiratory Flow: incapable measurement, cyanosis, head trip, disturbed consciousness, incontinence or asphyxia)</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Mild</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="26"/>
                <measurement group_id="B4" value="65"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Moderate</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Severe</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Serious</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline Forced Expiratory Volume in One Second (FEV1)</title>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1.4" spread="0.3"/>
                <measurement group_id="B2" value="1.2" spread="0.3"/>
                <measurement group_id="B3" value="1.4" spread="0.5"/>
                <measurement group_id="B4" value="1.3" spread="0.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Duration of Asthma</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14.9" spread="10.4"/>
                <measurement group_id="B2" value="13.9" spread="11.5"/>
                <measurement group_id="B3" value="16.7" spread="14.1"/>
                <measurement group_id="B4" value="15.2" spread="12.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration</title>
        <description>The Average of Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at 60 minutes after drug administration</description>
        <time_frame>60 minutes after drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last observed value during the 60 minutes treatment period was used in the Per Protocol Set (PPS). Three patients in Montelukast 7 mg were excluded due to the missing data (1 patient) and the protocol deviations (2 patients), and two patients in Aminophylline 250 mg were excluded due to the missing data from the PPS analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Montelukast 7 mg</title>
            <description>Montelukast 7 mg Intravenous Administration</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 14 mg</title>
            <description>Montelukast 14 mg Intravenous Administration</description>
          </group>
          <group group_id="O3">
            <title>Aminophylline 250 mg</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Improvement in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration</title>
            <description>The Average of Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at 60 minutes after drug administration</description>
            <units>Liter</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.07" lower_limit="0.02" upper_limit="0.12"/>
                  <measurement group_id="O2" value="0.05" lower_limit="0.00" upper_limit="0.11"/>
                  <measurement group_id="O3" value="0.06" lower_limit="0.01" upper_limit="0.12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.871</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included a factor for treatment and using the baseline Forced Expiratory Volume in One Second (FEV1) as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.794</p_value>
            <method>ANCOVA</method>
            <method_desc>The model included a factor for treatment and using the baseline Forced Expiratory Volume in One Second (FEV1) as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Montelukast 7 mg</title>
          <description>Montelukast 7 mg Intravenous Administration</description>
        </group>
        <group group_id="E2">
          <title>Montelukast 14 mg</title>
          <description>Montelukast 14 mg Intravenous Administration</description>
        </group>
        <group group_id="E3">
          <title>Aminophylline 250 mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
